Most evidence in favor of RAD50 rested on a truncating variant RAD50 c.687delT which has been observed in Finnish cases and controls [14,15]; while subsequent studies in the same and other populations are consistent with the hypothesis that RAD50 is an intermediate-risk breast or pancreatic cancer susceptibility gene, they have not provided significant supporting evidence [16,17]. This evidence concerns the gene RAD50 and pancreatic neoplasm.